What's in Region Skane's pipeline?

Region Skane has 6 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Region Skane's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/region-skane.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Region Skane — Portfolio Competitive Intelligence Brief

Region Skane pipeline: 5 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Methylprednisolone 80 mg	Methylprednisolone 80 mg	marketed
5% Albumin infusion 3 hours	5% Albumin infusion 3 hours	marketed	Plasma expanders	Intravascular volume and oncotic pressure	Hematology
L-menthol	L-menthol	marketed
vaccination with 2 doses of Shingrix vaccine	vaccination with 2 doses of Shingrix vaccine	marketed
Hypotonic riboflavin	Hypotonic riboflavin	marketed

Therapeutic area mix

Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Region Skane:

Cite this brief

Drug Landscape (2026). Region Skane — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/region-skane. Accessed 2026-05-15.